Cogito: A Turnkey Solution for Rapidly Developing, Evaluating, Deploying, and Scaling Digital Therapeutics

Launched by SQUARE2 SYSTEMS, INC. · Jul 29, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new digital tool called Cogito, which helps researchers quickly create and test digital therapies for health conditions like substance use disorders (SUDs). The platform is designed to be easy to use, allowing experts to build therapy programs by simply dragging and dropping components—no programming skills needed. In this first study, the focus is on seeing how user-friendly Cogito is when used to develop treatments specifically for people dealing with substance use issues.

The study is looking for participants who are experienced researchers or scientists (such as those with a PhD or MD) working in academic or digital health settings, with training in substance use disorder research and a clear interest in digital therapies for these conditions. Participants will help test the platform’s usability by using it to build digital treatment programs. This study is open to qualified adults of any gender, and it aims to improve and speed up the way digital therapies are created and shared to help people with SUDs.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • At least 18 years
• • PhD and/or MD-level (or equivalent) scientists at academic institutions or digital health companies at the level of Post-doctoral Fellow or higher.
• • Training or trained in substance use disorder (SUDs) research.
• • Must state a specific interest in digital therapeutics for SUDs.
• Exclusion Criteria:
• • Those who do not meet inclusion criteria.